表皮生长因子受体（EGFR）突变的肺癌对吉非替尼获得性耐药并携带L747S或T790M继发性突变时，对厄洛替尼的不同反应。 - Suppr

Suppr

超能文献

Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.

作者信息

Costa Daniel B, Schumer Susan T, Tenen Daniel G, Kobayashi Susumu

出版信息

J Clin Oncol. 2008 Mar 1;26(7):1182-4; author reply 1184-6. doi: 10.1200/JCO.2007.14.9039.

DOI:10.1200/JCO.2007.14.9039

PMID:18309959

Abstract

摘要

相似文献

Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.

J Clin Oncol. 2008 Mar 1;26(7):1182-4; author reply 1184-6. doi: 10.1200/JCO.2007.14.9039.

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

Clin Lung Cancer. 2009 Jul;10(4):281-9. doi: 10.3816/CLC.2009.n.039.

Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.

Clin Cancer Res. 2008 Nov 1;14(21):7060-7. doi: 10.1158/1078-0432.CCR-08-1455.

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

PLoS Med. 2005 Mar;2(3):e73. doi: 10.1371/journal.pmed.0020073. Epub 2005 Feb 22.

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.

PLoS Med. 2007 Oct;4(10):1669-79; discussion 1680. doi: 10.1371/journal.pmed.0040315.

The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.

Mol Cancer Ther. 2008 Apr;7(4):874-9. doi: 10.1158/1535-7163.MCT-07-2387.

Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.

Clin Cancer Res. 2009 Apr 15;15(8):2630-6. doi: 10.1158/1078-0432.CCR-08-2592. Epub 2009 Apr 7.

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.

Oncogene. 2009 Aug;28 Suppl 1(Suppl 1):S24-31. doi: 10.1038/onc.2009.198.

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

J Clin Oncol. 2010 Jan 10;28(2):357-60. doi: 10.1200/JCO.2009.24.7049. Epub 2009 Nov 30.

Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.

Ann Oncol. 2013 Aug;24(8):2080-7. doi: 10.1093/annonc/mdt127. Epub 2013 Apr 4.

引用本文的文献

[A Real-world Study on the Expression Characteristics of PD-L1 in Patients  with Advanced EGFR Positive NSCLC and Its Relationship with the  Therapeutic Efficacy of EGFR-TKIs].

Zhongguo Fei Ai Za Zhi. 2023 Mar 20;26(3):217-227. doi: 10.3779/j.issn.1009-3419.2023.101.09.

Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?

J Clin Med. 2023 Feb 10;12(4):1438. doi: 10.3390/jcm12041438.

Carbonic Anhydrase IX Controls Vulnerability to Ferroptosis in Gefitinib-Resistant Lung Cancer.

Oxid Med Cell Longev. 2023 Jan 31;2023:1367938. doi: 10.1155/2023/1367938. eCollection 2023.

Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma.

Oncol Lett. 2022 Sep 26;24(5):408. doi: 10.3892/ol.2022.13528. eCollection 2022 Nov.

Non-small-cell lung cancer: how to manage -mutated disease.

Drugs Context. 2022 Aug 3;11. doi: 10.7573/dic.2022-4-1. eCollection 2022.

[Targeted Therapy and Mechanism of Drug Resistance in Non-small Cell Lung Cancer  with Epidermal Growth Factor Receptor Gene Mutation].

Zhongguo Fei Ai Za Zhi. 2022 Mar 20;25(3):183-192. doi: 10.3779/j.issn.1009-3419.2022.101.05.

Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study.

Neurooncol Adv. 2021 Dec 27;4(1):vdab188. doi: 10.1093/noajnl/vdab188. eCollection 2022 Jan-Dec.

A Rare Presentation of a Non-Asian Female With Metastatic Non-small-cell Lung Cancer Harboring L747P Mutation With Clinical Response to Multi-targeted Epigenetic and Inhibition.

Anticancer Res. 2022 Jan;42(1):441-447. doi: 10.21873/anticanres.15502.

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC.

JTO Clin Res Rep. 2021 Nov 1;2(12):100252. doi: 10.1016/j.jtocrr.2021.100252. eCollection 2021 Dec.

Ubiquitin ligase SMURF2 enhances epidermal growth factor receptor stability and tyrosine-kinase inhibitor resistance.

J Biol Chem. 2020 Sep 4;295(36):12661-12673. doi: 10.1074/jbc.RA120.013519. Epub 2020 Jul 15.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验